What questions should I ask a perimenopausal patient at a one‑month follow‑up who started oral micronized progesterone and an estradiol transdermal patch for hormone replacement therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

One-Month HRT Follow-Up Questions for Perimenopausal Patient

At this one-month follow-up, your primary focus should be assessing symptom relief, identifying side effects, evaluating bleeding patterns, and screening for serious adverse events that would require immediate intervention.

Symptom Control Assessment

Vasomotor Symptoms

  • Hot flash frequency and severity: Ask specifically about the number of hot flashes per day/week and their intensity compared to baseline. Transdermal estradiol with oral micronized progesterone effectively treats vasomotor symptoms, with expected improvement within the first month 1.
  • Night sweats: Assess frequency and whether they disrupt sleep. Progesterone at 300 mg bedtime specifically improves both vasomotor symptoms and sleep quality 1.
  • Timing of symptoms: Determine if symptoms occur at specific times or are worse at certain points in the day.

Sleep Quality

  • Sleep onset and maintenance: Micronized progesterone (300 mg at bedtime) improves deep sleep and should show benefits by one month 1.
  • Number of nighttime awakenings: Distinguish between awakenings due to night sweats versus other causes.
  • Daytime fatigue or drowsiness: Progesterone can cause sedation, which may be beneficial for sleep but problematic if excessive 2.

Mood and Cognitive Function

  • Depressive symptoms: Screen for new or worsening depression, anxiety, or mood lability. The combination of transdermal estradiol and micronized progesterone can prevent depressive symptoms in early perimenopause 3.
  • Irritability or emotional changes: Ask about mood stability compared to pre-treatment.
  • Cognitive symptoms: Assess concentration, memory, or "brain fog."

Bleeding Pattern Evaluation

Critical Safety Assessment

  • Any vaginal bleeding: Document onset, duration, volume, and pattern. This is essential for endometrial safety monitoring 4.
    • Expected: Withdrawal bleeding 10-12 days after progesterone dosing (if on cyclic regimen)
    • Concerning: Unexpected breakthrough bleeding, heavy bleeding, or prolonged bleeding requiring evaluation
  • Bleeding timing relative to progesterone: Determine if bleeding occurs during or after the 12-day progesterone course.

Medication Adherence and Administration

Patch-Specific Questions

  • Patch adherence: Confirm twice-weekly application and proper rotation of sites 5.
  • Skin reactions: Ask about redness, itching, or irritation at application sites.
  • Patch adhesion: Determine if patches are staying on or falling off (especially with exercise, bathing, or sweating).

Progesterone-Specific Questions

  • Timing of administration: Confirm taking at bedtime to minimize daytime sedation 2.
  • Missed doses: Assess adherence to the 12-day monthly regimen.
  • Side effects: Specifically ask about dizziness, drowsiness, or headaches 2.

Serious Adverse Event Screening

Thromboembolic Risk (Critical)

  • Leg pain, swelling, or warmth: Screen for deep vein thrombosis. While transdermal estradiol has minimal VTE risk compared to oral estrogen 6, 7, this remains a critical safety concern 5.
  • Chest pain or shortness of breath: Rule out pulmonary embolism.
  • Sudden severe headache: Screen for stroke risk, particularly important in women over 60 5.
  • Visual changes: Ask about sudden vision loss or changes.

Cardiovascular Symptoms

  • Chest pain or pressure: Assess for cardiac symptoms 5.
  • Palpitations: Document frequency and severity.
  • Blood pressure: Measure at visit; transdermal estradiol may have favorable effects on blood pressure 8, 7.

Breast Health

  • Breast tenderness or pain: Common side effect that may improve with time 5.
  • New breast lumps: Requires immediate evaluation 5.

Genitourinary Symptoms

  • Vaginal dryness, itching, or burning: Assess if systemic HRT is adequately treating genitourinary symptoms 4, 5.
  • Dyspareunia: Ask about pain with intercourse.
  • Urinary symptoms: Frequency, urgency, or dysuria.

Other Side Effects

Common Side Effects to Assess

  • Headaches: Document frequency, severity, and timing 5, 2.
  • Nausea or abdominal discomfort: May occur with progesterone 2.
  • Bloating: Common with hormone therapy 5.
  • Weight changes: Document any significant changes.

Metabolic Considerations

  • Gallbladder symptoms: Right upper quadrant pain or digestive issues (transdermal estradiol has lower risk than oral) 5, 6.

Quality of Life Assessment

  • Overall satisfaction with treatment: Use a simple scale (1-10) for symptom relief.
  • Impact on daily activities: Assess work, exercise, social activities, and relationships.
  • Sexual function: Changes in libido or sexual satisfaction.

Risk Factor Reassessment

  • New medications: Screen for CYP3A4 inhibitors (e.g., ketoconazole) that may increase progesterone levels 2.
  • Smoking status: Critical risk factor for cardiovascular and thromboembolic events 5.
  • Stressful life events: May influence treatment response 3.
  • Family history updates: New diagnoses of breast cancer, VTE, or cardiovascular disease in family members.

Physical Examination Priorities

  • Blood pressure measurement: Essential at every visit 8.
  • Breast examination: Palpate for masses 5.
  • Skin examination: Check patch application sites for reactions.
  • Lower extremity examination: Assess for edema or signs of DVT if symptomatic.

Decision Points at One Month

If Symptoms Persist

  • Consider dose adjustment: May increase estradiol patch strength (e.g., from 0.05 mg to 0.1 mg) 4.
  • Verify proper patch application and adherence.
  • Reassess diagnosis and consider alternative causes of symptoms.

If Intolerable Side Effects

  • Excessive sedation from progesterone: Consider earlier evening dosing or dose reduction 2.
  • Skin reactions to patch: Switch application sites more frequently or consider alternative formulation.
  • Breakthrough bleeding: May require endometrial evaluation if heavy or prolonged 4.

If Doing Well

  • Reinforce adherence and continue current regimen.
  • Schedule next follow-up at 3-6 months per guideline recommendations 4, 5.
  • Emphasize warning signs requiring immediate contact: leg pain/swelling, chest pain, severe headache, visual changes, or abnormal vaginal bleeding 5.

Documentation Requirements

Document baseline symptom severity for comparison, current medication doses and regimen, any side effects or adverse events, physical examination findings including blood pressure, and the shared decision-making discussion about continuing therapy 4, 9.

References

1
Research

Progesterone for treatment of symptomatic menopausal women.

Climacteric : the journal of the International Menopause Society, 2018

4
Guideline

treatment of symptoms of the menopause: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

6
Research

What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone.

Climacteric : the journal of the International Menopause Society, 2012

Related Questions

In post‑menopausal women over 60, is transdermal estrogen‑plus‑progesterone therapy beneficial compared with oral hormone pills?
In hormone replacement therapy, can estradiol patches be combined with progesterone cream, or is oral progesterone required for endometrial protection?
Can oral micronized progesterone be used nightly as monotherapy for perimenopausal symptoms in a typical 45‑55‑year‑old woman without contraindications?
Can micronized progesterone be used to regulate menstrual cycles in a perimenopausal woman?
If I develop breast pain while using the Estalis (estradiol) transdermal patch, could switching to oral estradiol (Estramon) combined with oral micronized progesterone (Prometrium) alleviate the pain?
What does Courvoisier's law signify and what imaging is recommended for a jaundiced patient with a painless, palpable, distended gallbladder?
In a patient with autoimmune hepatitis on mycophenolate mofetil, can a Janus kinase (JAK) inhibitor be used to control his ulcerative colitis?
What are the normal partial pressure of oxygen (PO2) and partial pressure of carbon dioxide (PCO2) values in a venous blood gas (VBG)?
What medication can be used to treat sore nipples in a 66-year-old male receiving testosterone injections (0.3 mL twice weekly)?
What dose of amoxicillin-clavulanate should be given to an asthmatic patient with COPD, community-acquired pneumonia, and chronic dialysis-dependent renal failure?
What are the risks of tamoxifen in a 66‑year‑old male patient receiving testosterone therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.